A structured approach for the evaluation, validation, and implementation of NAT-based mycoplasma detection methods
Broadcast date
Thu, Jun 29, 2023
Presented by
- Mike Brewer - Thermo Fisher ScientificKevin McCarthy - Roche
Quick Description
Alternative adventitious agent detection methods, or adventitious agent tests (AATs) have been available for many years and the use of alternative AATs has been advocated by global regulatory authorities, but widespread adoption in the biotherapeutic industry has been slow. To address some of the challenges identified as roadblocks to the implementation of alternative AATs, this webinar provides case studies and best practice guidance for the validation of an alternative mycoplasma detection assay.
Details
Alternative adventitious agent detection methods, or adventitious agent tests (AATs) have been available for many years and the use of alternative AATs has been advocated by global regulatory authorities, but widespread adoption in the biotherapeutic industry has been slow. To address some of the challenges identified as roadblocks to the implementation of alternative AATs, this webinar provides case studies and best practice guidance for the validation of an alternative mycoplasma detection assay.It also includes an example of completing a user requirement specification (URS) for evaluating an alternative mycoplasma detection assay, validation, and implementation. Strategies are also provided to help identify suitable technologies for defined applications. Finally, a framework is presented to demonstrate how a validation protocol for an alternative mycoplasma detection assay can be executed to meet the regulatory expectation that the alternative method is equivalent to or better than the current compendial methods (culture method and indicator cell culture method).
Speakers
Mike Brewer
Director, Global Principal Consultant, Regulatory, BioProduction
Thermo Fisher Scientific
Kevin McCarthy
QR Scientist
Roche